Discovering KDM3A: A Potential Drug Target and Biomarker (G55818)

Target Name: KDM3A

NCBI ID: G55818

KDM3A

Discovering KDM3A: A Potential Drug Target and Biomarker

KDM3A (also known as JMJD1) is a gene that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its discovery and research into its potential uses have generated a lot of interest and discussion in the scientific community.

KDM3A is a gene that is located on chromosome 16 and encodes for a protein known as NIMA. NIMA is a key regulator of microRNA (miRNA) levels, which are small non-coding RNAs that play a crucial role in post-transcriptional gene regulation. miRNA molecules are made by the microRNA machinery, which is a complex of RNA binding proteins, and they act by targetsing specific mRNAs for degradation or translation into proteins.

Studies have shown that NIMA is involved in a wide range of biological processes, including cell growth, apoptosis (programmed cell death), and immune responses. It has also been implicated in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key reasons for the interest in KDM3A is its potential as a drug target. By targeting NIMA, researchers can potentially inhibit the activity of this protein and disrupt its role in various biological processes. This could lead to a range of potential therapeutic benefits, including the treatment of diseases that are currently untreatable or have limited treatment options.

In addition to its potential as a drug target, KDM3A has also been identified as a potential biomarker for several diseases. The ability to use KDM3A as a biomarker is based on its expression levels, which can be measured using techniques such as qRT-PCR (Quantitative Real-Time polymerase chain reaction) or western blotting. By analyzing the expression levels of KDM3A in patient samples, researchers can potentially identify biomarkers that are associated with disease progression or response to therapy.

KDM3A has been shown to be expressed in a variety of tissues and cells, including cancer cells, immune cells, and neural stem/progenitor cells. It has also been shown to be involved in the regulation of miRNA levels, which suggests that it may play a role in the miRNA-mediated regulation of gene expression. This is consistent with its potential as a drug target, as drugs that target miRNA pathways have been shown to be effective in treating a variety of diseases.

In addition to its potential as a drug target and biomarker, KDM3A is also of interest because of its location on chromosome 16. Chromosome 16 is a gene therapy target for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its location on this chromosome suggests that it may be a good candidate for gene therapy, where genes are introduced into the cells to treat a genetic disease.

Overall, the discovery and research of KDM3A has generated a lot of interest and discussion in the scientific community. Its potential as a drug target and biomarker make it an promising target for future research, and its location on chromosome 16 suggests that it may be a good candidate for gene therapy. Further studies are needed to fully understand its role in these processes and to develop effective treatments for the diseases that it is involved in.

Protein Name: Lysine Demethylase 3A

Functions: Histone demethylase that specifically demethylates 'Lys-9' of histone H3, thereby playing a central role in histone code. Preferentially demethylates mono- and dimethylated H3 'Lys-9' residue, with a preference for dimethylated residue, while it has weak or no activity on trimethylated H3 'Lys-9'. Demethylation of Lys residue generates formaldehyde and succinate. Involved in hormone-dependent transcriptional activation, by participating in recruitment to androgen-receptor target genes, resulting in H3 'Lys-9' demethylation and transcriptional activation. Involved in spermatogenesis by regulating expression of target genes such as PRM1 and TNP1 which are required for packaging and condensation of sperm chromatin. Involved in obesity resistance through regulation of metabolic genes such as PPARA and UCP1

The "KDM3A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KDM3A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets